Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study
Status:
Suspended
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and bioactivity of an herbal supplement
called "kansui," which contains several active ingredients such as ingenols that may have a
role in helping clear HIV from the body. Kansui has been used in traditional Chinese medicine
for centuries to treat various ailments such as for eliminating excess fluid in the abdomen
or lungs, loosening phlegm from the chest, and relieving constipation. Based on preliminary
in vitro data from our group, kansui extract powder is a potent activator of HIV
transpcription in latently infected Jurkat cells. The investigators' hypothesis is that
kansui extract powder prepared as tea will be safe and well-tolerated, elicit an in vivo
immunologic response, and at the doses administered, increase HIV transcription in
latently-infected cells among HIV-infected patients on suppressive antiretroviral therapy.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
amfAR, The Foundation for AIDS Research Center for AIDS Research (CFAR) University of Utah